ACT-HIB 30 MCG / 0.5 ML — DIN 01959034
TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML · SANOFI PASTEUR LIMITED · KIT ; POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ACT-HIB?
ACT-HIB 30 MCG / 0.5 ML contains TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 01959034, held by SANOFI PASTEUR LIMITED, supplied as KIT ; POWDER FOR SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 14-Jul-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT-HIB used for?
Act-HIB® is indicated for the active immunization of children 2 months of age and older for the prevention of invasive disease caused by Haemophilus influenzae type b. Routine immunization against invasive disease caused by H. influenzae type b in infants and children between 2 to 59 months of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Hemophilus Influenzae B, Purified Antig. Conjugated cost around the world?
Hemophilus Influenzae B, Purified Antig. Conjugated is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Czechia | max producer price (ex-factory) | 1 | 1 |
| Iceland | max wholesale | 1 | 1 |
2 pack listings across 2 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Hemophilus Influenzae B, Purified Antig. Conjugated pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Hemophilus Influenzae B, Purified Antig. Conjugated in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Hemophilus Influenzae B, Purified Antig. Conjugated, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI PASTEUR LIMITED | 1 | 1 | ACT-HIB | Sourceable in Canada |
| MERCK CANADA INC | 1 | 0 | LIQUID PEDVAXHIB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MCG / 0.5 ML |
|---|---|
| Dosage form | KIT ; POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | Available in packages containing five single-dose vials of Act-HIB® and five x 0.5 mL (single dose vials of Sanofi Pasteur Limited’s DILUENT, 0.4% Saline for reconstitution of Act-HIB®. Also supplied in packages containing five single dose vials of Act-HIB® and five x 0.5 mL (single dose) vial of Sanofi Pasteur Limited's QUADRACEL® to be used for reconstitution in place of the Act-HIB® diluent and sold under the tradename PENTACEL®. Also supplied in one or five dose packages containing either one or five single dose vials of Act-HIB® and one or five x 0.5 mL (single dose) vials of Sanofi Pasteur Limited's TRIPACEL® to be used for reconstitution in place of the Act-HIB® diluent and sold under the tradename ACTACEL®. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Hemophilus Influenzae B, Purified Antig. Conjugated |
|---|---|
| ATC code | J07AG01 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01959034 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1959034 |
| Brand name | ACT-HIB |
| Generic / active ingredient | TETANUS PROTEIN : 30 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP : 10 MCG / 0.5 ML |
| Market authorization holder | SANOFI PASTEUR LIMITED |
| Health Canada schedule | Schedule D |
| ATC code | J07AG01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AG |
| Current status | MARKETED |
| Status date | 14-Jul-2006 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| LIQUID PEDVAXHIB | 125 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | CANCELLED POST MARKET | 02235721 |
2 · Same class — other molecules in ATC J07AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hemophilus Influenzae B, Purified Antig. Conjugated | ACT-HIB · LIQUID PEDVAXHIB | 2 | 1 | Yes |
| Hemophilus Influenzae B, Combinations With Toxoids | HIBERIX · HIBTITER SOL INJ · PROHIBIT INJ VACCINE | 3 | 0 | Not in Canada |
| Hemophilus Influenzae B, Combinations With Pertussis And Toxoids | ACTACEL · ACTACEL HYBRID | 2 | 0 | Not in Canada |
| Hemophilus Influenzae B Vaccines | PEDVAXHIB INJ PWS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AH | Meningococcal Vaccines · Meningococcus B, Multicomponent Vaccine · Meningococcus C, Purified Polysaccharides Antigen Conjugated · Meningococcus, A, C, Bivalent Purified Polysacc. Antigen · Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen · +1 more | 17 | 6 |
| J07AL | Pneumococcus, Purified Polysacc.antigen Conjugated · Pneumococcus, Purified Polysaccharides Antigen | 11 | 3 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AF | Diphtheria Toxoid | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACT-HIB called?
The same molecule, Hemophilus Influenzae B, Purified Antig. Conjugated, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| HIBERIX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.